XenoPort, Inc.

Quick facts

Marketed products

• GSK1838262 600 mg
• GSK1838262 Placebo match
  GSK1838262 is a placebo match formulation designed to mimic the appearance and administration of an active pharmaceutical agent for use in blinded clinical trials.
• Sinemet (comparator) · Neurology
  Sinemet combines levodopa (a dopamine precursor) with carbidopa (a decarboxylase inhibitor) to increase dopamine levels in the brain while preventing peripheral conversion of levodopa.

Phase 3 pipeline

• GEn (XP13512) · Neurology
  XP13512 is a prodrug of gabapentin that uses a novel amino acid transporter-mediated delivery system to enhance absorption and bioavailability in the gastrointestinal tract.
• GSK1838262 Extended Release Tablets · Diabetes
  GSK1838262 is a selective inhibitor of sodium-dependent glucose cotransporter 1 (SGLT1) that reduces intestinal glucose absorption.
• XP13512 (GEn)
• XP13512 (GSK1838262) · Neurology
  XP13512 is a voltage-gated sodium channel blocker.

Phase 2 pipeline

• GSK1838262
• XP13512

Phase 1 pipeline

• Carbidopa Pill
• Sinemet 25-100 Oral Tablet
• XP21279

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• XenoPort, Inc. portfolio CI brief
• XenoPort, Inc. pipeline updates RSS